Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
IPO Year: 1999
Exchange: NYSE
Website: agilent.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $157.00 | Overweight | Wells Fargo |
7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
6/3/2024 | $135.00 | Hold | Jefferies |
4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
12/13/2023 | $140.00 | Outperform | Wolfe Research |
12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
11/17/2023 | $163.00 → $125.00 | Buy → Neutral | UBS |
9/28/2023 | $123.00 | Mkt Perform | Bernstein |
7/31/2023 | $126.00 → $124.00 | Outperform → In-line | Evercore ISI |
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Agilent Technologies Inc. (NYSE:A) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET. CEO Padraig McDonnell, CFO Bob McMahon, and other senior business leaders will present information regarding Agilent's strategy, businesses, and long-term financial outlook. The event will conclude with a Q&A session. This in-person event is by invitation only, but a live webcast will be accessible through Agilent's Investor Relations website. A replay of the event will be available for at least 60 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and inno
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with $65 billion of capital under management, is pleased to announce the sale of its portfolio company, BIOVECTRA Inc. ("BIOVECTRA" or the "Company"), a leading contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients and intermediates, to Agilent Technologies, Inc. (NYSE:A) for a purchase price of $925 million. Headquartered in Charlottetown, Prince Edward Island, Canada, BIOVECTRA has approximately 650 employees and eight facilities with over 270,000 square feet of facility space. The Company produces biologics, highly potent active pharmaceutical ingredients, and other molecule
Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities Agilent Technologies Inc. (NYSE:A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919413644/en/(Graphic: Business Wire) All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent's Diagnostics and Genomics Group. "
LEWISVILLE, Ark., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium") (TSXV:SLI) (NYSE:A), a leading near-commercial lithium development and technology company and Equinor, a global energy leader, today announced that its jointly-owned U.S. subsidiary, SWA Lithium LLC has been selected for up to US$225 million award negotiation from the U.S. Department of Energy ("DOE"). This selection, overseen by the DOE's Office of Manufacturing and Energy Supply Chains (MESC), is one of the largest ever awarded to a U.S. critical minerals project and is part of the second wave of funding under the Infrastructure Investment and Jobs Act aimed at expanding domestic manufacturing
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' m
Details How Independent Third Parties and the Evidence in Legal Proceedings Have Consistently Refuted Masimo's "Defensive Rhetoric" and How Company's Attacks on Politan Continue to "Crumble Under Basic Scrutiny" Shareholders Can Vote for Politan's Independent Nominees, Darlene Solomon and William Jellison, on the WHITE Card and Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today issued an open letter to shareholders in advance of the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"), set for September 19. Th
New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization Agilent Technologies Inc., (NYSE:A) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance. These credentials signify that the lab operates in accordance with CLIA regulations, which are federal standards applicable to all U.S. facilities testing human specimens for health assessment, diagnosis, prevention, or treatment of diseases. The CLIA certificate of compliance
Delivers better-than-expected performance; raises midpoint of guidance Highlights Revenue of $1.58 billion, down 5.6% reported and 4.4% core(1) from the third quarter of 2023. GAAP net income of $282 million; earnings per share (EPS) of $0.97, up 155% from the third quarter of 2023. Non-GAAP(2) net income of $385 million; EPS of $1.32, down 8% from the third quarter of 2023. Full-year revenue outlook revised at $6.450 billion to $6.500 billion. Fiscal year 2024 non-GAAP(3) earnings guidance also revised at a range of $5.21 to $5.25 per share. Fourth-quarter revenue outlook expected at $1.641 billion to $1.691 billion with non-GAAP(3) EPS of $1.38 to $1.42. Agilent Techno
Agilent Technologies Inc., (NYSE:A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent's industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications. In modern gas chromatography/mass spectrometry (GC/MS) workflows, GC/MS columns are often subjected to complex matrices and chemically active analytes th
MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA®, a MAGE-A4-directed engineered T-Cell Receptor (TCR) therapy is being considered Agilent Technologies Inc., (NYSE:A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy. MAGE-A4 (melanoma-associated antigen A4) is a cancer-testis antigen overexpressed in various cancers, including synovial sarcoma. MAG
Agilent Technologies's (NYSE:A) short percent of float has risen 45.05% since its last report. The company recently reported that it has 4.15 million shares sold short, which is 1.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.16 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inte
Agilent Technologies (NYSE:A) has outperformed the market over the past 10 years by 1.49% on an annualized basis producing an average annual return of 12.38%. Currently, Agilent Technologies has a market capitalization of $38.17 billion. Buying $1000 In A: If an investor had bought $1000 of A stock 10 years ago, it would be worth $3,228.78 today based on a price of $130.82 for A at the time of writing. Agilent Technologies's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automa
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs raised the price target for Tesla, Inc. (NASDAQ:TSLA) from $175 to $248. Goldman Sachs analyst Mark Delaney maintained a Neutral rating. Tesla shares rose 3.7% to close at $262.33 on Tuesday. See how other analysts view this stock. Keybanc lifted the price target for Netflix, Inc. (NASDAQ:NFLX) from $707 to $735. Keybanc analyst Justin Patterson maintained an Overweight rating. Netflix shares closed at $685.74 on Tuesday. See how other analysts view this stock. B of A Securities cu
Citigroup analyst Patrick Donnelly upgrades Agilent Technologies (NYSE:A) from Neutral to Buy and raises the price target from $135 to $150.
Evercore ISI Group analyst Ross Muken maintains Agilent Technologies (NYSE:A) with a In-Line and raises the price target from $126 to $130.
Wolfe Research analyst Doug Schenkel downgrades Agilent Technologies (NYSE:A) from Outperform to Peer Perform.
Agilent Technologies (NYSE:A) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 7 2 0 Last 30D 0 0 1 0 0 1M Ago 2 2 5 1 0 2M Ago 0 0 0 0 0 3M Ago 1 0 1 1 0 In the assessment of 12-month price targets, analysts unveil insights for Agilent Technologies, presenting an average target of $141.0, a high estimate of $163.00, and a low estimate of $125.00. This current avera
B of A Securities analyst Derik De Bruin maintains Agilent Technologies (NYSE:A) with a Neutral and raises the price target from $134 to $140.
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00
Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously
Wolfe Research downgraded Agilent from Outperform to Peer Perform
Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00
Stifel upgraded Agilent from Hold to Buy and set a new price target of $163.00 from $145.00 previously
Wolfe Research initiated coverage of Agilent with a rating of Outperform and set a new price target of $140.00
BofA Securities downgraded Agilent from Buy to Neutral and set a new price target of $133.00 from $130.00 previously
UBS downgraded Agilent from Buy to Neutral and set a new price target of $125.00 from $163.00 previously
Bernstein initiated coverage of Agilent with a rating of Mkt Perform and set a new price target of $123.00
Evercore ISI downgraded Agilent from Outperform to In-line and set a new price target of $124.00 from $126.00 previously
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
424B5 - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
FWP - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
424B5 - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
S-3ASR - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8
New instrument delivers the full power and capability of Agilent GCs in a compact design Agilent Technologies Inc., (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%. Modern labs face the seemingly contrasting goals of maximizing analytical capacity with limited bench space while reducing the overall environmental impact of their opera
Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501393789/en/Padraig McDonnell (Photo: Business Wire) "It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life," McDonnell said. "I'm proud of how we forge partnerships with our
SAN FRANCISCO, CA, June 22, 2021 (GLOBE NEWSWIRE) -- Fundbox, the financial platform for small businesses, announced today that it has appointed Hilliard Terry to its Board of Directors. Mr. Terry is an experienced executive leader, corporate board member and advisor to private equity backed portfolio companies. Mr. Terry currently serves on the board of directors of Umpqua Holdings Corporation (NASDAQ:UMPQ), a financial services company. He also serves on the board of directors of Upstart Holdings, Inc. (NASDAQ:UPST), a leading artificial intelligence consumer lending platform, and on the board of TLG Acquisition One Corporation (NYSE:TLGA), a special purpose acquisition company. "H
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.(NYSE: A) is pleased to announce Allison Ballmer has been named the company’s new senior vice president of Strategy and Corporate Development, reporting to Agilent President and CEO Mike McMullen. Ballmer will lead the corporate development team in identifying, developing, and evaluating merger-and-acquisition plans globally, as well as program management of integrations. She also will lead enterprise strategy while collaborating with Agilent businesses groups to drive critical growth initiatives across the company. Ballmer will serve as a key member of the executive staff and as an adviser to the CEO to help shape th
DUBLIN, Jan. 11, 2021 /PRNewswire/ -- Aon plc (NYSE: AON), the leading global professional services firm providing a broad range of risk, retirement and health solutions, announced today that the Board of Directors has declared a quarterly cash dividend of $0.46 per share on outstanding Class A Ordinary Shares. The dividend is payable February 12, 2021 to shareholders of record on February 1, 2021. About Aon Aon plc (NYSE: AON) Aon is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatilit
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' m
Delivers better-than-expected performance; raises midpoint of guidance Highlights Revenue of $1.58 billion, down 5.6% reported and 4.4% core(1) from the third quarter of 2023. GAAP net income of $282 million; earnings per share (EPS) of $0.97, up 155% from the third quarter of 2023. Non-GAAP(2) net income of $385 million; EPS of $1.32, down 8% from the third quarter of 2023. Full-year revenue outlook revised at $6.450 billion to $6.500 billion. Fiscal year 2024 non-GAAP(3) earnings guidance also revised at a range of $5.21 to $5.25 per share. Fourth-quarter revenue outlook expected at $1.641 billion to $1.691 billion with non-GAAP(3) EPS of $1.38 to $1.42. Agilent Techno
Technology helps high-throughput labs operate more efficiently Agilent Technologies Inc. (NYSE:A) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Financial terms of the acquisition were not disclosed. Sigsense technology is already available to Agilent customers through CrossLab Connect, a suite of digital applications—inventory management, service management, asset monitoring, smart alerts, and asset lifecycle analytics—that improve lab performance. Integrated into the Agilent CrossLab Connect asset monitoring solution, Sigsense's algorithm tracks i
Agilent Technologies Inc. (NYSE:A) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of so
Full-year outlook revised to reflect slower market recovery Announces plan to repurchase $0.75 billion of its common stock by end of fiscal year Board of directors authorizes new $2.0 billion share repurchase program Highlights Revenue of $1.57 billion, down 8.4% reported and 7.4% core(1) from the second quarter of 2023. GAAP net income of $308 million; earnings per share (EPS) of $1.05, up 3% from the second quarter of 2023. Non-GAAP(2) net income of $356 million; EPS of $1.22, down 4% from the second quarter of 2023. Full-year revenue outlook revised at $6.420 billion to $6.500 billion, representing a range of down 6.0% to 4.9% on a reported basis and down 5.4% to 4.3% core(
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on July 24, 2024, to all shareholders of record as of the close of business on July 2, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers
Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of sol
Revenue and earnings exceed Q1 guidance Full-year outlook maintained Highlights Revenue of $1.66 billion, down 5.6% reported and 6.4% core(1) from the first quarter of 2023. GAAP net income of $348 million; earnings per share (EPS) of $1.18, down 1% from the first quarter of 2023. Non-GAAP(2) net income of $380 million; EPS of $1.29, down 6% from the first quarter of 2023. Full-year revenue outlook maintained at $6.710 billion to $6.810 billion, representing a range of down 1.8% to 0.3% on a reported basis and down 0.5% to up 1% core(1). Fiscal year 2024 non-GAAP(3) earnings guidance also maintained at a range of $5.44 to $5.55 per share. Second-quarter revenue outlook expe
Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on April 24, 2024, to all shareholders of record as of the close of business on April 2, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customer
Agilent Technologies Inc. (NYSE:A) today announced the company was again named one of the Most JUST Companies in America by Just Capital and CNBC. This marks the sixth year Agilent has appeared on the exclusive list, and the fourth year the company has ranked in the top 50. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212230027/en/ The list highlights 100 companies that are performing best on business issues that matter most to the U.S. public, from paying a living wage and creating jobs to prioritizing accountability to all stakeholders. "It's an honor to be included in the JUST 100," said Neil Rees, Agilent's head of En